KR20150090263A - 헤지호그 신호전달에 대한 피리딜 억제제 - Google Patents

헤지호그 신호전달에 대한 피리딜 억제제 Download PDF

Info

Publication number
KR20150090263A
KR20150090263A KR1020157019595A KR20157019595A KR20150090263A KR 20150090263 A KR20150090263 A KR 20150090263A KR 1020157019595 A KR1020157019595 A KR 1020157019595A KR 20157019595 A KR20157019595 A KR 20157019595A KR 20150090263 A KR20150090263 A KR 20150090263A
Authority
KR
South Korea
Prior art keywords
chloro
pyridin
phenyl
methyl
give
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020157019595A
Other languages
English (en)
Korean (ko)
Inventor
자넷 건츠너
대니얼 서덜린
마크 스탠리
량 바오
게오르게트 카스타네도
레베카 랄론드
슈메이 왕
마크 레이놀즈
스코트 새비지
킴벌리 말레스키
마이클 디나
마이클 에프. 티. 코울러
Original Assignee
제넨테크, 인크.
쿠리스 인코퍼레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35517336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20150090263(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 제넨테크, 인크., 쿠리스 인코퍼레이션 filed Critical 제넨테크, 인크.
Publication of KR20150090263A publication Critical patent/KR20150090263A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/141—Esters of phosphorous acids
    • C07F9/142—Esters of phosphorous acids with hydroxyalkyl compounds without further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Medicines Containing Plant Substances (AREA)
KR1020157019595A 2004-09-02 2005-09-02 헤지호그 신호전달에 대한 피리딜 억제제 Withdrawn KR20150090263A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60736704P 2004-09-02 2004-09-02
US60/607,367 2004-09-02
PCT/US2005/031284 WO2006028958A2 (en) 2004-09-02 2005-09-02 Pyridyl inhibitors of hedgehog signalling

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020147032534A Division KR20150002863A (ko) 2004-09-02 2005-09-02 헤지호그 신호전달에 대한 피리딜 억제제

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020167012485A Division KR20160058972A (ko) 2004-09-02 2005-09-02 헤지호그 신호전달에 대한 피리딜 억제제

Publications (1)

Publication Number Publication Date
KR20150090263A true KR20150090263A (ko) 2015-08-05

Family

ID=35517336

Family Applications (13)

Application Number Title Priority Date Filing Date
KR1020187032025A Ceased KR20180122750A (ko) 2004-09-02 2005-09-02 헤지호그 신호전달에 대한 피리딜 억제제
KR1020077007426A Expired - Lifetime KR101225018B1 (ko) 2004-09-02 2005-09-02 헤지호그 신호전달에 대한 피리딜 억제제
KR1020147032534A Withdrawn KR20150002863A (ko) 2004-09-02 2005-09-02 헤지호그 신호전달에 대한 피리딜 억제제
KR1020197017288A Ceased KR20190072678A (ko) 2004-09-02 2005-09-02 헤지호그 신호전달에 대한 피리딜 억제제
KR1020167012485A Withdrawn KR20160058972A (ko) 2004-09-02 2005-09-02 헤지호그 신호전달에 대한 피리딜 억제제
KR1020167036072A Ceased KR20170001725A (ko) 2004-09-02 2005-09-02 헤지호그 신호전달에 대한 피리딜 억제제
KR1020207004242A Withdrawn KR20200019263A (ko) 2004-09-02 2005-09-02 헤지호그 신호전달에 대한 피리딜 억제제
KR1020207028744A Ceased KR20200118909A (ko) 2004-09-02 2005-09-02 헤지호그 신호전달에 대한 피리딜 억제제
KR1020137017403A Withdrawn KR20130083488A (ko) 2004-09-02 2005-09-02 헤지호그 신호전달에 대한 피리딜 억제제
KR1020147008628A Withdrawn KR20140048343A (ko) 2004-09-02 2005-09-02 헤지호그 신호전달에 대한 피리딜 억제제
KR1020217021887A Ceased KR20210090744A (ko) 2004-09-02 2005-09-02 헤지호그 신호전달에 대한 피리딜 억제제
KR1020157019595A Withdrawn KR20150090263A (ko) 2004-09-02 2005-09-02 헤지호그 신호전달에 대한 피리딜 억제제
KR1020127029702A Expired - Fee Related KR101366414B1 (ko) 2004-09-02 2005-09-02 헤지호그 신호전달에 대한 피리딜 억제제

Family Applications Before (11)

Application Number Title Priority Date Filing Date
KR1020187032025A Ceased KR20180122750A (ko) 2004-09-02 2005-09-02 헤지호그 신호전달에 대한 피리딜 억제제
KR1020077007426A Expired - Lifetime KR101225018B1 (ko) 2004-09-02 2005-09-02 헤지호그 신호전달에 대한 피리딜 억제제
KR1020147032534A Withdrawn KR20150002863A (ko) 2004-09-02 2005-09-02 헤지호그 신호전달에 대한 피리딜 억제제
KR1020197017288A Ceased KR20190072678A (ko) 2004-09-02 2005-09-02 헤지호그 신호전달에 대한 피리딜 억제제
KR1020167012485A Withdrawn KR20160058972A (ko) 2004-09-02 2005-09-02 헤지호그 신호전달에 대한 피리딜 억제제
KR1020167036072A Ceased KR20170001725A (ko) 2004-09-02 2005-09-02 헤지호그 신호전달에 대한 피리딜 억제제
KR1020207004242A Withdrawn KR20200019263A (ko) 2004-09-02 2005-09-02 헤지호그 신호전달에 대한 피리딜 억제제
KR1020207028744A Ceased KR20200118909A (ko) 2004-09-02 2005-09-02 헤지호그 신호전달에 대한 피리딜 억제제
KR1020137017403A Withdrawn KR20130083488A (ko) 2004-09-02 2005-09-02 헤지호그 신호전달에 대한 피리딜 억제제
KR1020147008628A Withdrawn KR20140048343A (ko) 2004-09-02 2005-09-02 헤지호그 신호전달에 대한 피리딜 억제제
KR1020217021887A Ceased KR20210090744A (ko) 2004-09-02 2005-09-02 헤지호그 신호전달에 대한 피리딜 억제제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020127029702A Expired - Fee Related KR101366414B1 (ko) 2004-09-02 2005-09-02 헤지호그 신호전달에 대한 피리딜 억제제

Country Status (27)

Country Link
US (8) US7888364B2 (cg-RX-API-DMAC10.html)
EP (1) EP1789390B1 (cg-RX-API-DMAC10.html)
JP (3) JP5143558B2 (cg-RX-API-DMAC10.html)
KR (13) KR20180122750A (cg-RX-API-DMAC10.html)
CN (2) CN101072755A (cg-RX-API-DMAC10.html)
AT (1) ATE532768T1 (cg-RX-API-DMAC10.html)
AU (3) AU2005282722C1 (cg-RX-API-DMAC10.html)
BE (1) BE2013C071I2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0514841B1 (cg-RX-API-DMAC10.html)
CA (1) CA2579002C (cg-RX-API-DMAC10.html)
CY (2) CY1112630T1 (cg-RX-API-DMAC10.html)
DK (1) DK1789390T3 (cg-RX-API-DMAC10.html)
EA (3) EA201100604A1 (cg-RX-API-DMAC10.html)
ES (1) ES2377430T3 (cg-RX-API-DMAC10.html)
FR (1) FR14C0002I2 (cg-RX-API-DMAC10.html)
HU (1) HUS1300068I1 (cg-RX-API-DMAC10.html)
IL (2) IL181673A (cg-RX-API-DMAC10.html)
LU (1) LU92278I2 (cg-RX-API-DMAC10.html)
MX (1) MX2007002584A (cg-RX-API-DMAC10.html)
NO (1) NO339260B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ589385A (cg-RX-API-DMAC10.html)
PL (1) PL1789390T3 (cg-RX-API-DMAC10.html)
PT (1) PT1789390E (cg-RX-API-DMAC10.html)
SI (1) SI1789390T1 (cg-RX-API-DMAC10.html)
UA (1) UA96565C2 (cg-RX-API-DMAC10.html)
WO (1) WO2006028958A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200702537B (cg-RX-API-DMAC10.html)

Families Citing this family (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2295316T3 (es) * 2001-01-13 2008-04-16 University Of North Carolina At Chapel Hill Compuestos, metodos y composiciones utiles para el tratamiento de la infeccion por virus de la diarrea virica bovina (bvdv) e infeccion por virus de la hepatitis c (hcv).
CA2579002C (en) 2004-09-02 2012-11-27 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
AU2005287729A1 (en) 2004-09-22 2006-03-30 H. Lundbeck A/S 2-acylaminothiazole derivatives
US7674912B2 (en) 2005-04-25 2010-03-09 H. Lundbeck A/S Pro-drugs of N-thiazol-2-yl-benzamide derivatives
WO2006134467A1 (en) * 2005-06-16 2006-12-21 Pfizer Inc. N-(pyridin-2-yl)-sulfonamide derivatives
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
EP2013628B1 (en) * 2006-04-28 2016-01-06 Momenta Pharmaceuticals, Inc. Methods of evaluating peptide mixtures
UA93548C2 (uk) * 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
CN101679308B (zh) 2007-03-14 2014-05-07 埃克塞里艾克西斯公司 Hedgehog途径抑制剂
UA100684C2 (uk) * 2007-03-15 2013-01-25 Новартіс Аг Похідні бензилу та піридинілу як модулятори сигнального шляху hedgehog
NZ580457A (en) 2007-04-06 2012-03-30 Neurocrine Biosciences Inc Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
US8263588B2 (en) 2007-04-06 2012-09-11 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
AU2008241527B2 (en) 2007-04-18 2014-02-13 Merck Sharp & Dohme Llc Triazole derivatives which are Smo antagonists
EP2162190B1 (en) * 2007-06-07 2016-02-17 Novartis AG Biphenylcarboxamide derivatives as hedgehog pathway modulators
US20100216828A1 (en) 2007-08-16 2010-08-26 Christine Dierks Methods and compositions for treating cancers
TW200918521A (en) * 2007-08-31 2009-05-01 Astrazeneca Ab Heterocyclic amides and methods of use thereof
UY31322A1 (es) * 2007-09-05 2009-04-30 Amidas heterocíclicas y sus métodos de uso-975
DE102007042754A1 (de) 2007-09-07 2009-03-12 Bayer Healthcare Ag Substituierte 6-Phenylnikotinsäuren und ihre Verwendung
CA2697682A1 (en) 2007-09-07 2009-03-19 Amgen Inc. Annelated pyridazines for the treatment of tumors driven by inapropriate hedgehog signalling
BRPI0818658A2 (pt) 2007-10-09 2015-04-14 Merck Patent Ges Mit Beschränkter Haftung Derivados de piridina úteis como ativadores de glicoquinase
GB0725214D0 (en) * 2007-12-24 2008-02-06 Karobio Ab Pharmaceutical compounds
US8716479B2 (en) 2007-12-27 2014-05-06 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US20090281089A1 (en) * 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
US7981892B2 (en) * 2008-04-29 2011-07-19 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
US20120094974A1 (en) * 2008-06-17 2012-04-19 Wei Chen Smoothened receptor modulators
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
MX2011002060A (es) 2008-08-25 2011-04-05 Irm Llc Moduladores de la senda de hedgehog.
EP2346499A1 (en) * 2008-10-01 2011-07-27 Novartis AG Smoothened antagonism for the treatment of hedgehog pathway-related disorders
MX2011004683A (es) * 2008-11-03 2011-06-20 Lilly Co Eli Antagonistas de la via hedgehog de ftalazina disustituida.
WO2010056620A1 (en) 2008-11-17 2010-05-20 Eli Lilly And Company Tetrasubstituted pyridazines hedgehog pathway antagonists
US8507490B2 (en) 2008-11-17 2013-08-13 Eli Lilly And Company Tetrasubstituted pyridazine hedgehog pathway antagonists
EA020496B1 (ru) 2008-11-21 2014-11-28 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Производное адамантилбензамида, фармацевтическая композиция, включающая его, и его применение
US8748623B2 (en) 2009-02-17 2014-06-10 Syntrix Biosystems, Inc. Pyridinecarboxamides as CXCR2 modulators
EP2233566A1 (en) 2009-03-17 2010-09-29 Vrije Universiteit Brussel Generation of pancreatic progenitor cells
FR2943669B1 (fr) * 2009-03-24 2011-05-06 Sanofi Aventis Derives de nicotinamide,leur preparation et leur application en therapeutique
US9345699B2 (en) 2009-06-09 2016-05-24 Nantbioscience, Inc. Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
FR2948367A1 (fr) 2009-07-24 2011-01-28 Centre Nat Rech Scient Derives d'acyl-guanidines modulateurs de la voie de signalisation des proteines hedgehog
WO2011014888A1 (en) * 2009-07-31 2011-02-03 Selexagen Therapeutics Novel hedgehog inhibitors
CN102574791A (zh) 2009-08-05 2012-07-11 无限药品股份有限公司 环杷明类似物的酶促转氨基反应
WO2011085128A1 (en) 2010-01-07 2011-07-14 Selexagen Therapeutics, Inc. Hedgehog inhibitors
EP2571357B1 (en) 2010-05-21 2016-07-06 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
WO2011156321A1 (en) 2010-06-07 2011-12-15 Novomedix, Llc Furanyl compounds and the use thereof
WO2012015715A1 (en) 2010-07-27 2012-02-02 High Point Pharmaceuticals, Llc Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta hsd1 modulators
JP6486002B2 (ja) * 2010-08-23 2019-03-20 シントリックス・バイオシステムズ・インコーポレイテッドＳｙｎｔｒｉｘ Ｂｉｏｓｙｓｔｅｍｓ， Ｉｎｃ． Ｃｘｃｒ２モジュレーターとしてのアミノピリジンカルボキサミドおよびアミノピリミジンカルボキサミド
WO2012037217A1 (en) 2010-09-14 2012-03-22 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
FR2965263A1 (fr) * 2010-09-24 2012-03-30 Sanofi Aventis Derives de thienopyridine nicotinamide, leur preparation et leur application en therapeutique
CN103298474B (zh) 2010-11-10 2016-06-29 无限药品股份有限公司 杂环化合物及其用途
FR2967498B1 (fr) 2010-11-16 2015-01-02 Centre Nat Rech Scient Utilisation de derives de quinolinone comme outil de recherche
EP2468726B1 (en) 2010-12-06 2013-08-28 Siena Biotech S.p.A. Compound for the treatment of tumours and tumour metastases
TWI574687B (zh) * 2011-01-03 2017-03-21 古利斯股份有限公司 具有鋅結合部份之刺蝟拮抗劑
US9708299B2 (en) 2011-01-03 2017-07-18 Genentech, Inc. Hedgehog antagonists having zinc binding moieties
MX347708B (es) 2011-01-10 2017-05-09 Infinity Pharmaceuticals Inc Proceso para preparar isoquinolinonas y formas solidas de isoquinolinonas.
US9181266B2 (en) 2011-07-13 2015-11-10 Novartis Ag 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
CN103814032A (zh) 2011-07-13 2014-05-21 诺华股份有限公司 用作端锚聚合酶抑制剂的4-氧代-3,5,7,8-四氢-4H-吡喃并[4,3-d]嘧啶基化合物
US9163003B2 (en) 2011-07-13 2015-10-20 Novartis Ag 4-piperidinyl compounds for use as tankyrase inhibitors
CN103946226A (zh) 2011-07-19 2014-07-23 无限药品股份有限公司 杂环化合物及其应用
AU2012284088B2 (en) 2011-07-19 2015-10-08 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
HK1199725A1 (en) 2011-08-29 2015-07-17 无限药品股份有限公司 Heterocyclic compounds and uses thereof
FR2980477B1 (fr) 2011-09-23 2013-10-18 Centre Nat Rech Scient Nouveaux composes modulateurs de la voie de signalisation des proteines hedgehog, leurs formes marquees, et applications
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
WO2013105022A2 (en) 2012-01-09 2013-07-18 Novartis Ag Organic compositions to treat beta-catenin-related diseases
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN102731373B (zh) * 2012-07-19 2013-11-27 南京药石药物研发有限公司 抗肿瘤药物gdc-0449中间体的制备方法
CN103570625A (zh) * 2012-07-19 2014-02-12 南京英派药业有限公司 N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用
EP2895474B1 (en) 2012-09-17 2019-12-11 Duke University Smoothened receptor modulators and methods of use thereof
RU2702908C2 (ru) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
JP6293770B2 (ja) * 2012-11-05 2018-03-14 ナント ホールディングス アイピー，エルエルシー ヘッジホッグシグナル伝達経路阻害剤としての環状スルホンアミド含有誘導体
US9844541B2 (en) 2012-11-29 2017-12-19 Strasspharma, Llc Methods of modulating follicle stimulating hormone activity
CN103910671B (zh) * 2013-01-08 2016-08-10 正大天晴药业集团股份有限公司 Vismodegib及其中间体的制备方法
CN103910672B (zh) * 2013-01-08 2016-10-05 连云港润众制药有限公司 Vismodegib的制备方法
CN103040824B (zh) * 2013-01-17 2015-05-27 四川大学 信号通路抑制剂及其制备方法和用途
CA2899030C (en) 2013-02-19 2021-03-09 Novartis Ag Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
NZ629037A (en) 2013-03-15 2017-04-28 Infinity Pharmaceuticals Inc Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9278932B1 (en) 2013-03-22 2016-03-08 Shilpa Medicare Limited Process for preparation of 2-chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide solid forms
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
CN103254124A (zh) * 2013-04-23 2013-08-21 镇江圣安医药有限公司 N-[4-氯-3–(吡啶-2-基)苯基]-2-氯-4–(甲磺酰基)-苯甲酰胺衍生物及其应用
RU2019134551A (ru) 2013-05-30 2019-11-22 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
WO2014195977A2 (en) * 2013-06-05 2014-12-11 Hetero Research Foundation Novel polymorphs of vismodegib
US8969365B2 (en) 2013-08-02 2015-03-03 Syntrix Biosystems, Inc. Thiopyrimidinecarboxamides as CXCR1/2 modulators
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US10561676B2 (en) 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
HUE057734T2 (hu) 2013-10-04 2022-06-28 Infinity Pharmaceuticals Inc Heterociklusos vegyületek és alkalmazásuk
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015092634A1 (en) 2013-12-16 2015-06-25 Novartis Ag 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
ES2699354T3 (es) 2014-01-17 2019-02-08 Novartis Ag Derivados de 1-(triazin-3-il/piridazin-3-il)-piper(-azin)idina y composiciones de las mismas para inhibir la actividad de SHP2
ES2699351T3 (es) 2014-01-17 2019-02-08 Novartis Ag Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
CN113616656B (zh) 2014-03-19 2023-02-17 无限药品股份有限公司 用于治疗PI3K-γ介导的障碍的杂环化合物
SG11201607973XA (en) 2014-03-24 2016-11-29 Guangdong Zhongsheng Pharmaceutical Co Ltd Quinoline derivatives as smo inhibitors
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
WO2015169269A1 (en) 2014-05-05 2015-11-12 Zentiva, K.S. Salts of 2-chloro-n-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide
EP3140298A1 (en) 2014-05-07 2017-03-15 Pfizer Inc. Tropomyosin-related kinase inhibitors
WO2016020324A1 (en) * 2014-08-07 2016-02-11 Basf Se Multi-component crystals of vismodegib and selected co-crystal formers or solvents
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2963281A1 (en) 2014-10-03 2016-04-07 Novartis Ag Combination therapies
CN104496889A (zh) * 2014-11-20 2015-04-08 成都平和安康医药科技有限公司 一种工业化合成维莫地尼的方法
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
US9765050B2 (en) 2014-12-30 2017-09-19 Novira Therapeutics, Inc. Pyridyl reverse sulfonamides for HBV treatment
WO2016151499A1 (en) 2015-03-25 2016-09-29 Novartis Ag Formylated n-heterocyclic derivatives as fgfr4 inhibitors
US10369147B2 (en) 2015-06-04 2019-08-06 PellePharm, Inc. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
US10464897B2 (en) * 2015-06-05 2019-11-05 Dana-Farber Cancer Institute, Inc. Compounds and methods for treating cancer
CN107787323B (zh) 2015-06-19 2020-09-01 诺华股份有限公司 用于抑制shp2活性的化合物和组合物
WO2016203404A1 (en) 2015-06-19 2016-12-22 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
JP6718889B2 (ja) 2015-06-19 2020-07-08 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための化合物および組成物
CN104926714B (zh) * 2015-07-02 2017-07-28 天津大学 2‑氯‑n‑(4‑氯‑3‑(2‑吡啶基)苯基)‑4‑甲基砜苯基苯甲酰胺的制备方法
EP3350183B1 (en) 2015-09-14 2025-04-02 Twelve Therapeutics, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017050224A1 (zh) * 2015-09-21 2017-03-30 广东众生药业股份有限公司 喹啉衍生物的盐型、晶型及其制备方法和中间体
CN105524056A (zh) * 2016-01-05 2016-04-27 中山大学肿瘤防治中心 一种氨基噻唑化合物及其制备方法和应用
US20170231968A1 (en) 2016-02-11 2017-08-17 PellePharm, Inc. Method for relief of and treatment of pruritus
EP3429571B1 (en) 2016-03-15 2025-10-08 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
ES2849560T3 (es) 2016-05-04 2021-08-19 Genoscience Pharma Sas Derivados de 2,4-diamino-quinolina sustituidos para su uso en el tratamiento de enfermedades proliferativas
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
RU2744988C2 (ru) 2016-06-14 2021-03-17 Новартис Аг Соединения и композиции для подавления активности shp2
MX391135B (es) 2016-06-24 2025-03-21 Infinity Pharmaceuticals Inc Terapias de combinacion.
US10280164B2 (en) 2016-09-09 2019-05-07 Incyte Corporation Pyrazolopyridone compounds and uses thereof
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
CN115819417A (zh) 2016-09-09 2023-03-21 因赛特公司 作为hpk1调节剂的吡唑并吡啶衍生物及其用于治疗癌症的用途
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
US10548908B2 (en) * 2016-09-15 2020-02-04 Nostopharma, LLC Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
WO2018121610A1 (zh) * 2016-12-27 2018-07-05 山东大学 针对Smoothened突变株的刺猬通路抑制剂
WO2018133114A1 (en) * 2017-01-23 2018-07-26 Shenzhen University Novel natrural algicide with low toxicity to non-target organisms
US20180228786A1 (en) 2017-02-15 2018-08-16 Incyte Corporation Pyrazolopyridine compounds and uses thereof
CN106892863B (zh) * 2017-03-09 2019-06-11 山东大学 维莫德吉及其中间体的制备方法
GB2560903A (en) * 2017-03-27 2018-10-03 Azad Pharmaceutical Ingredients Ag New synthetic path to pharmaceutically acceptable vismodegib
CN107200708B (zh) * 2017-05-27 2020-03-20 新发药业有限公司 一种维莫德吉的制备方法
CN107556289A (zh) * 2017-06-22 2018-01-09 天津国际生物医药联合研究院 一种氯苯‑吡啶类化合物及其应用
GB201713784D0 (en) * 2017-08-29 2017-10-11 E-Therapeutics Plc Modulators of hedgehog (Hh) Signalling pathway
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
TWI851542B (zh) 2017-09-11 2024-08-11 美商克魯松藥物公司 Ｓｈｐ２之八氫環戊烷并[c]吡咯別構抑制劑
KR102708050B1 (ko) 2018-01-31 2024-09-24 데시페라 파마슈티칼스, 엘엘씨. 비만 세포증의 치료를 위한 병용 요법
SG11202007198WA (en) 2018-01-31 2020-08-28 Deciphera Pharmaceuticals Llc Combination therapy for the treatment of gastrointestinal stromal tumors
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
DK3755703T3 (da) 2018-02-20 2022-06-27 Incyte Corp N-(phenyl)-2-(phenyl)pyrimidin-4-carboxamidderivater og relaterede forbindelser som hpk1-inhibitorer til behandling af kræft
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
KR102831570B1 (ko) 2018-05-04 2025-07-10 레미디 플랜, 인크. 암 줄기 세포를 표적화하는 암 치료
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
JP2022500499A (ja) 2018-09-07 2022-01-04 ピク セラピューティクス， インコーポレイテッド Ｅｉｆ４ｅ阻害剤およびその使用
FI3853234T3 (fi) 2018-09-18 2025-07-28 Nikang Therapeutics Inc Fuusioituja trisyklisiä rengasjohdannaisia SRC-homologia-2-fosfataasin estäjinä
ES2973117T3 (es) 2018-09-25 2024-06-18 Incyte Corp Compuestos de pirazolo[4,3-d]pirimidina como moduladores de ALK2 y/o FGFR
CN113164776A (zh) 2018-09-25 2021-07-23 黑钻治疗公司 酪氨酸激酶抑制剂组合物、其制备方法和使用方法
WO2020068867A1 (en) 2018-09-25 2020-04-02 Black Diamond Therapeutics, Inc. Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
EP3856345A1 (en) 2018-09-29 2021-08-04 Novartis AG Process of manufacture of a compound for inhibiting the activity of shp2
WO2020072540A1 (en) * 2018-10-03 2020-04-09 Nantbio, Inc. A dual inhibitor of wnt/beta-catenin & sonic hedgehog signal transduction pathways
DK3643713T3 (da) * 2018-10-23 2025-11-03 Iomx Therapeutics Ag Heterocykliske kinaseinhibitorer og deres anvendelse
US11739078B2 (en) 2019-02-22 2023-08-29 Insilico Medicine Ip Limited Methods of inhibiting kinases
EP3938363A1 (en) 2019-03-11 2022-01-19 Teva Pharmaceuticals International GmbH Solid state forms of ripretinib
US20220040207A1 (en) * 2019-04-02 2022-02-10 The University Of Chicago Remodilins to prevent or treat cancer metastasis, glaucoma, and hypoxia
JP2022543155A (ja) 2019-08-06 2022-10-07 インサイト・コーポレイション Ｈｐｋ１阻害剤の固体形態
CN114615982A (zh) 2019-08-12 2022-06-10 德西费拉制药有限责任公司 用于治疗胃肠道间质瘤的瑞普替尼
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
CN114787150A (zh) 2019-08-15 2022-07-22 黑钻治疗公司 炔基喹唑啉化合物
MX2022008103A (es) 2019-12-30 2022-09-19 Deciphera Pharmaceuticals Llc Formulaciones de inhibidores de la cinasa amorfa y metodos de estas.
CN118948772A (zh) 2019-12-30 2024-11-15 德西费拉制药有限责任公司 1-(4溴-5-(1乙基-7-(甲氨基)-2侧氧基-1,2-二氢-1,6-萘啶-3基)-2氟苯基)-3-苯基脲的组合物
MX2022010944A (es) 2020-03-03 2022-11-09 Pic Therapeutics Inc Inhibidores del factor de iniciacion de traduccion eucariotica 4e (eif4e) y sus usos.
WO2021195206A1 (en) 2020-03-24 2021-09-30 Black Diamond Therapeutics, Inc. Polymorphic forms and related uses
JP7327855B2 (ja) 2020-06-26 2023-08-16 ラクオリア創薬株式会社 レチノイドとがん治療薬との併用療法が有効ながん患者の選択方法およびレチノイドとがん治療薬との併用医薬
WO2022043556A1 (en) 2020-08-31 2022-03-03 Novartis Ag Stable radiopharmaceutical composition
WO2022043558A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
US20230321285A1 (en) 2020-08-31 2023-10-12 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
EP4229828A4 (en) 2020-10-13 2024-08-28 Endeavor Biomedicines, Inc. METHODS OF TREATMENT OF FIBROSIS
WO2022140472A1 (en) 2020-12-22 2022-06-30 Nikang Therapeutics, Inc. Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
WO2022152821A1 (en) 2021-01-13 2022-07-21 Monte Rosa Therapeutics Ag Isoindolinone compounds
WO2022170052A1 (en) 2021-02-05 2022-08-11 Black Diamond Therapeutics, Inc. Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof
WO2022211811A1 (en) 2021-03-31 2022-10-06 Genentech, Inc. Vismodegib in combination with a replication-deficient type 5 adenovirus for expression of interferon gamma for the treatment of skin cancer
EP4323349A1 (en) 2021-04-14 2024-02-21 Monte Rosa Therapeutics AG Isoindolinone amide compounds useful to treat diseases associated with gspt1
WO2022219407A1 (en) 2021-04-14 2022-10-20 Monte Rosa Therapeutics Ag Isoindolinone compounds
TW202317589A (zh) 2021-07-14 2023-05-01 美商尼坎醫療公司 作為ｋｒａｓ抑制劑的伸烷基衍生物
WO2023028235A1 (en) 2021-08-25 2023-03-02 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
CN118019739A (zh) 2021-08-25 2024-05-10 皮克医疗公司 Eif4e抑制剂及其用途
GB202201283D0 (en) * 2022-02-01 2022-03-16 Omass Therapeutics Ltd Pharmaceutical compounds
US20250171462A1 (en) * 2022-03-02 2025-05-29 Nico Therapeutics, Inc. Compounds, compositions, and methods
US12331026B2 (en) 2022-03-28 2025-06-17 Nikang Therapeutics, Inc. Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors
EP4504705A1 (en) 2022-04-05 2025-02-12 Synthon B.V. Solid forms of vismodegib
EP4536363A1 (en) 2022-06-08 2025-04-16 Nikang Therapeutics, Inc. Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
EP4615833A1 (en) 2022-11-11 2025-09-17 Nikang Therapeutics, Inc. Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
WO2025072462A1 (en) 2023-09-27 2025-04-03 Nikang Therapeutics, Inc. Sulfonamide derivatives as cyclin-dependent kinase 2 inhibitors
TW202527955A (zh) 2023-11-27 2025-07-16 美商尼坎醫療公司 用於經由泛素蛋白酶體途徑降解週期蛋白依賴性激酶２和週期蛋白依賴性激酶４的含有２，５－取代的嘧啶衍生物的雙功能化合物
WO2025117981A1 (en) 2023-12-02 2025-06-05 Nikang Therapeutics, Inc. Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
US12447148B2 (en) 2024-03-05 2025-10-21 Endeavor Biomedicines, Inc. Methods of improving lung function
WO2025212828A1 (en) 2024-04-03 2025-10-09 Nikang Therapeutics, Inc. Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and cyclin-dependent kinase 4 via ubiquitin proteasome pathway
WO2025240536A1 (en) 2024-05-15 2025-11-20 Nikang Therapeutics, Inc. Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and/or cyclin-dependent kinase 4 via ubiquitin proteasome pathway

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0167491A3 (de) * 1984-07-06 1986-12-30 Ciba-Geigy Ag Thiobarbitursäurederivate
JPH0813741B2 (ja) 1987-08-10 1996-02-14 協和醗酵工業株式会社 抗痴呆剤
JPH02196721A (ja) * 1989-01-24 1990-08-03 Green Cross Corp:The 抗癌剤
DE4323916A1 (de) 1993-07-16 1995-01-19 Basf Ag Substituierte 2-Phenylpyridine
CA2173326A1 (en) * 1993-10-06 1995-04-13 Lucian Radu Denes Herbicidal heteroaryl substituted anilides
DE19500758A1 (de) 1995-01-13 1996-07-18 Basf Ag Substituierte 2-Phenylpyridine
NZ301265A (en) 1995-02-02 1998-12-23 Smithkline Beecham Plc Indole derivatives as 5ht receptor antagonists, preparation and pharmaceutical compositions thereof
WO1997003967A1 (en) 1995-07-22 1997-02-06 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
DE60017157T2 (de) * 1999-09-16 2005-12-22 Curis, Inc., Cambridge Vermittler von igel signalwegen, deren zusammenstellungen und verwendungen
FR2801305B1 (fr) * 1999-11-24 2002-12-06 Galderma Res & Dev Analogues de la vitamine d
US7115653B2 (en) * 2000-03-30 2006-10-03 Curis, Inc. Small organic molecule regulators of cell proliferation
US6683192B2 (en) 2000-03-30 2004-01-27 Curis, Inc. Small organic molecule regulators of cell proliferation
US6645990B2 (en) * 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
JP2004511538A (ja) * 2000-10-17 2004-04-15 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 殺昆虫性１，８−ナフタレンジカルボキサミド類
JP4083422B2 (ja) * 2000-12-22 2008-04-30 石原産業株式会社 アニリン誘導体またはその塩ならびにそれらを含有するサイトカイン産生抑制剤
KR20030064852A (ko) * 2000-12-22 2003-08-02 이시하라 산교 가부시끼가이샤 아닐린 유도체 또는 그의 염 및 이들을 함유하는사이토카인 생산 억제제
US7687664B2 (en) 2001-06-04 2010-03-30 Eisai R&D Management Co., Ltd. Carboxylic acid derivative, a salt thereof or an ester of them, and medicament comprising it
KR20040031782A (ko) 2001-07-27 2004-04-13 쿠리스 인코퍼레이션 헤지호그 신호전달 경로의 조절물질, 이를 함유하는조성물 및 이의 용도
EP1427705A2 (en) * 2001-09-21 2004-06-16 E.I. Du Pont De Nemours And Company Insecticidal diamides
GB0124928D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124932D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
EP1451160B1 (en) * 2001-11-01 2010-01-13 Icagen, Inc. Pyrazole-amides for use in the treatment of pain
JPWO2003051876A1 (ja) 2001-12-14 2005-04-28 日本たばこ産業株式会社 ピラゾロピリジン誘導体およびその医薬用途
WO2003059258A2 (en) 2001-12-21 2003-07-24 Cytokinetics, Inc. Compositions and methods for treating heart failure
PL212910B1 (pl) * 2002-02-12 2012-12-31 Smithkline Beecham Corp Pochodna nikotynoamidu, srodek farmaceutyczny i zastosowanie pochodnej nikotynoamidu
AU2003245700A1 (en) * 2002-02-12 2003-09-04 Glaxo Group Limited Pyrazolopyridine derivatives
EP1572693A1 (en) 2002-12-20 2005-09-14 Pharmacia Corporation Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
WO2005033288A2 (en) * 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
WO2005040152A1 (en) * 2003-10-20 2005-05-06 E.I. Dupont De Nemours And Company Heteroyclylphenyl-and heterocyclylpyridyl-substituted azolecarboxamides as herbicides
US20070185152A1 (en) 2004-03-02 2007-08-09 Smithkline Beecham Corporation Inhibitors of akt activity
WO2005113494A2 (en) * 2004-05-07 2005-12-01 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
CA2579002C (en) * 2004-09-02 2012-11-27 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
US20090281089A1 (en) 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling

Also Published As

Publication number Publication date
KR101225018B1 (ko) 2013-01-23
MX2007002584A (es) 2007-09-07
US20240116872A1 (en) 2024-04-11
CA2579002C (en) 2012-11-27
DK1789390T3 (da) 2012-02-27
CY2013042I1 (el) 2015-12-09
EP1789390B1 (en) 2011-11-09
KR20190072678A (ko) 2019-06-25
AU2005282722C1 (en) 2011-08-18
KR20200118909A (ko) 2020-10-16
CY1112630T1 (el) 2015-12-09
PT1789390E (pt) 2012-02-08
UA96565C2 (ru) 2011-11-25
FR14C0002I1 (fr) 2014-02-14
EA017262B1 (ru) 2012-11-30
ES2377430T3 (es) 2012-03-27
IL181673A (en) 2013-12-31
US20150105550A1 (en) 2015-04-16
BE2013C071I2 (cg-RX-API-DMAC10.html) 2024-10-09
KR20150002863A (ko) 2015-01-07
US20180029984A1 (en) 2018-02-01
US9321761B2 (en) 2016-04-26
US20160152569A1 (en) 2016-06-02
EA201890903A9 (ru) 2021-11-10
US20200010420A1 (en) 2020-01-09
SI1789390T1 (sl) 2012-05-31
ATE532768T1 (de) 2011-11-15
KR20120139846A (ko) 2012-12-27
IL181673A0 (en) 2007-07-04
LU92278I2 (fr) 2013-11-11
CY2013042I2 (el) 2015-12-09
BRPI0514841B1 (pt) 2021-10-26
PL1789390T3 (pl) 2012-04-30
LU92278I9 (cg-RX-API-DMAC10.html) 2019-03-06
KR20140048343A (ko) 2014-04-23
EA201100604A1 (ru) 2014-06-30
US9278961B2 (en) 2016-03-08
NO339260B1 (no) 2016-11-21
KR20160058972A (ko) 2016-05-25
KR20200019263A (ko) 2020-02-21
US20060063779A1 (en) 2006-03-23
FR14C0002I2 (fr) 2014-11-21
KR101366414B1 (ko) 2014-03-18
BRPI0514841A (pt) 2008-06-24
NZ589385A (en) 2011-03-31
AU2005282722B2 (en) 2011-03-03
US20210070707A1 (en) 2021-03-11
US7888364B2 (en) 2011-02-15
CN102964294A (zh) 2013-03-13
WO2006028958A2 (en) 2006-03-16
KR20180122750A (ko) 2018-11-13
JP5143558B2 (ja) 2013-02-13
JP2008511675A (ja) 2008-04-17
EP1789390A2 (en) 2007-05-30
EA201890903A1 (ru) 2019-02-28
US20110092461A1 (en) 2011-04-21
WO2006028958A3 (en) 2006-04-13
KR20170001725A (ko) 2017-01-04
KR20210090744A (ko) 2021-07-20
EA200700538A1 (ru) 2007-10-26
KR20070085243A (ko) 2007-08-27
CN101072755A (zh) 2007-11-14
AU2023237067A1 (en) 2023-10-12
AU2011201229A1 (en) 2011-04-14
IL214451A0 (en) 2011-09-27
US9790183B2 (en) 2017-10-17
NO20071719L (no) 2007-05-31
JP2014148537A (ja) 2014-08-21
HUS1300068I1 (hu) 2019-03-28
ZA200702537B (en) 2008-08-27
JP2012184255A (ja) 2012-09-27
KR20130083488A (ko) 2013-07-22
CA2579002A1 (en) 2006-03-16
AU2005282722A1 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
KR101643781B1 (ko) 헤지호그 신호전달에 대한 피리딜 억제제
US20240116872A1 (en) Pyridyl inhibitors for hedgehog signalling
AU2017261491A1 (en) Pyridyl Inhibitors of Hedgehog Signalling

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20150720

Application number text: 1020147032534

Filing date: 20141120

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150819

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20151112

Patent event code: PE09021S01D

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20160610

WITB Written withdrawal of application